Atlas Trials

A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC

Clinical trial NCT04398108 · COMPLETED

Trial details

NCT number
NCT04398108
Sponsor
Zai Lab (Shanghai) Co., Ltd.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
HER2 Positive Metastatic Breast Cancer
Start date
2020-08-25
Primary completion
2021-04-27
Enrollment
16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.